Next Article in Journal
Synthesis and Antiplasmodial Activity of 3-Furyl and 3-Thienylquinoxaline-2-carbonitrile 1,4-Di-N-oxide Derivatives
Next Article in Special Issue
Synthesis and Structural Analysis of Polyester Prodrugs of Norfloxacin
Previous Article in Journal
A New Phenolic Amide from the Roots of Paris verticillata
Previous Article in Special Issue
Efficacy of DA-7218, a New Oxazolidinone Prodrug, in the Treatment of Experimental Actinomycetoma Produced by Nocardia brasiliensis
Molecules 2008, 13(1), 46-68; doi:10.3390/molecules13010046

Antiparkinson Prodrugs

* ,  and
Received: 4 December 2007 / Revised: 11 January 2008 / Accepted: 11 January 2008 / Published: 16 January 2008
(This article belongs to the collection Prodrugs)
Download PDF [183 KB, uploaded 18 June 2014]
Abstract: Parkinson`s disease (PD) is a progressive, neurodegenerative disorder whichinvolves the loss of dopaminergic neurons of the substantia nigra pars compacta. Currenttherapy is essentially symptomatic, and L-Dopa (LD), the direct precursor of dopamine(DA), is the treatment of choice in more advanced stages of the disease. Substitutiontherapy with LD is, however, associated with a number of acute problems. The peripheralconversion of LD by amino acid decarboxylase (AADC) to DA is responsible for thetypical gastrointestinal (nausea, emesis) and cardiovascular (arrhythmia, hypotension) sideeffects. To minimize the conversion to DA outside the central nervous system (CNS) LD isusually given in combination with peripheral inhibitors of AADC (carbidopa andbenserazide). In spite of that, other central nervous side effects such as dyskinesia, on-offphenomenon and end-of-dose deterioration still remain. The main factors responsible forthe poor bioavailability and the wide range of inter- and intra-patient variations of plasmalevels are the drug’s physical-chemical properties: low water and lipid solubility, resultingin unfavourable partition, and the high susceptibility to chemical and enzymaticdegradation. In order to improve the bioavailability, the prodrug approach appeared to bethe most promising and some LD prodrugs have been prepared in an effort to solve theseproblems. We report here a review of progress in antiparkinson prodrugs, focusing onchemical structures mainly related to LD, DA and dopaminergic agonists.
Keywords: L-dopa; Dopamine; Prodrugs; antiparkinson L-dopa; Dopamine; Prodrugs; antiparkinson
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |

MDPI and ACS Style

Di Stefano, A.; Sozio, P.; Cerasa, L.S. Antiparkinson Prodrugs. Molecules 2008, 13, 46-68.

AMA Style

Di Stefano A, Sozio P, Cerasa LS. Antiparkinson Prodrugs. Molecules. 2008; 13(1):46-68.

Chicago/Turabian Style

Di Stefano, Antonio; Sozio, Piera; Cerasa, Laura S. 2008. "Antiparkinson Prodrugs." Molecules 13, no. 1: 46-68.

Molecules EISSN 1420-3049 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert